Deliang X. Fu

12 Wulumuqi Middle Road
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 103 publications

HRD Score: A Promising Biomarker for Genomic Instability Evaluation for Targeted Treatments Among Pancreatic Cancer Patients.

HRD Score: A Promising Biomarker for Genomic Instability Evaluation for Targeted Treatments Among Pancreatic Cancer Patients.

Journal: Technology in cancer research & treatment

Published: July 14, 2026

Parenchyma-sparing pancreatectomy for solid pseudopapillary neoplasm of the pancreas: A propensity-matched analysis.

Parenchyma-sparing pancreatectomy for solid pseudopapillary neoplasm of the pancreas: A propensity-matched analysis.

Journal: Surgery

Published: April 15, 2026

Endoscopic ultrasound-guided pancreaticogastrostomy using lumen-apposing metal stent to manage a case of pseudocyst and pancreatic duct dilation after severe acute pancreatitis.

Endoscopic ultrasound-guided pancreaticogastrostomy using lumen-apposing metal stent to manage a case of pseudocyst and pancreatic duct dilation after severe acute pancreatitis.

Journal: Endoscopy

Published: April 02, 2026

Extracellular vesicles from chemotherapy-induced senescent tumor cells reprogram hepatic phospholipid metabolism to promote pancreatic cancer liver metastasis.

Extracellular vesicles from chemotherapy-induced senescent tumor cells reprogram hepatic phospholipid metabolism to promote pancreatic cancer liver metastasis.

Journal: Journal of experimental & clinical cancer research : CR

Published: February 14, 2026

Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial.

Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 11, 2025

Periarterial divestment for borderline and locally advanced pancreatic cancer: An analysis of 125 cases in a single center.

Periarterial divestment for borderline and locally advanced pancreatic cancer: An analysis of 125 cases in a single center.

Journal: Surgery

Published: January 03, 2025

Ubiquitin-specific protease 7 maintains c-Myc stability to support pancreatic cancer glycolysis and tumor growth.

Ubiquitin-specific protease 7 maintains c-Myc stability to support pancreatic cancer glycolysis and tumor growth.

Journal: Journal of translational medicine

Published: August 14, 2024

Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma.

Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma.

Journal: BMC medicine

Published: May 31, 2024

Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.

Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.

Journal: Signal transduction and targeted therapy

Published: March 28, 2024

Integrating plasma protein-centric multi-omics to identify potential therapeutic targets for pancreatic cancer.

Integrating plasma protein-centric multi-omics to identify potential therapeutic targets for pancreatic cancer.

Journal: Journal of translational medicine

Published: March 22, 2024

Ionizable cationic lipid nanoparticles loaded with miRNA-125b/BLZ945 for pancreatic cancer treatment.

Ionizable cationic lipid nanoparticles loaded with miRNA-125b/BLZ945 for pancreatic cancer treatment.

Journal: Biotechnology and applied biochemistry

Published: March 10, 2024

Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial.

Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial.

Journal: Oncology letters

Published: September 25, 2023

Showing 1-12 of 103

Last Updated: 09/26/2026